Cargando…

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management

Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the m...

Descripción completa

Detalles Bibliográficos
Autores principales:	da Cunha Colombo Bonadio, Renata Rodrigues, Fogace, Rodrigo Nogueira, Miranda, Vanessa Costa, Diz, Maria del Pilar Estevez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096977/ https://www.ncbi.nlm.nih.gov/pubmed/30133561 http://dx.doi.org/10.6061/clinics/2018/e450s

Ejemplares similares

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Ovarian cancer risk assessment in the era of next-generation sequencing
por: Bonadio, Renata Colombo, et al.
Publicado: (2020)

Management of cervical cancer patients during the COVID-19 pandemic: a challenge for developing countries
por: del Pilar Estevez-Diz, Maria, et al.
Publicado: (2020)

Everolimus plus anastrozole for female adnexal tumor of probable Wolffian origin (FATWO) with STK11 mutation
por: Estevez-Diz, Maria de Pilar, et al.
Publicado: (2021)

Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis
por: Rodrigues da Cunha Colombo Bonadio, Renata, et al.
Publicado: (2018)

A matched case-control study of the prognosis of early breast cancer in patients with Li-Fraumeni syndrome (BREAST TP53)
por: Petry, Vanessa, et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on breast and cervical cancer stage at diagnosis in Brazil
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial
por: Nunes de Arruda, Fernanda, et al.
Publicado: (2020)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
por: van Wijk, Lise M., et al.
Publicado: (2020)

Late Isolated Central Nervous System Relapse from Ovarian Serous Adenocarcinoma: A Case Report and Literature Review
por: de Castria, Tiago Biachi, et al.
Publicado: (2014)

Homologous Recombination Deficiencies and Hereditary Tumors
por: Yamamoto, Hideki, et al.
Publicado: (2021)

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
por: Watkins, Johnathan A, et al.
Publicado: (2014)

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
por: Takaya, Hisamitsu, et al.
Publicado: (2020)

Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
por: Chiang, Ying-Cheng, et al.
Publicado: (2021)

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches
por: Mangogna, Alessandro, et al.
Publicado: (2023)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities
por: Zielli, Teresa, et al.
Publicado: (2023)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature
por: Frey, Melissa K., et al.
Publicado: (2017)

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma
por: Shi, Zhiwen, et al.
Publicado: (2021)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Pan-cancer landscape of homologous recombination deficiency
por: Nguyen, Luan, et al.
Publicado: (2020)

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
por: Wattenberg, Max M., et al.
Publicado: (2021)

Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022)

Targeting homologous recombination deficiency in uterine leiomyosarcoma
por: Dall, Genevieve, et al.
Publicado: (2023)

Leveraging homologous recombination repair deficiency in sarcoma
por: Slade, Dea, et al.
Publicado: (2023)

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023)

Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma
por: Liu, Hangqi, et al.
Publicado: (2022)

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
por: How, Jeffrey A., et al.
Publicado: (2021)

Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination
por: Setton, Jeremy, et al.
Publicado: (2021)

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
por: Quesada, Stanislas, et al.
Publicado: (2022)

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations
por: Quesada, Stanislas, et al.
Publicado: (2022)

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
por: Ngoi, N.Y.L., et al.
Publicado: (2021)

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer
por: Wen, Hao, et al.
Publicado: (2022)

Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer
por: Simoes Correa-Galendi, Julia, et al.
Publicado: (2020)

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis
por: Guarischi-Sousa, Rodrigo, et al.
Publicado: (2023)

Homologous recombination proficiency in ovarian and breast cancer patients
por: Creeden, Justin Fortune, et al.
Publicado: (2021)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_24rjj6of74hfu3d2087qu3t444